Angina pectoris has the characteristics of long duration, difficult to cure and easy to recur, thus seriously affects the quality of survival of patients. blockers are commonly used in the treatment of angina pectoris in coronary heart disease, but there are cases of drug resistance and adverse effects. There is evidence demonstrating that Tongxinluo capsules are reliable and safe in the treatment of angina pectoris in coronary heart disease. However, there is a lack of high-quality clinical stu
Conditions
Interventions
Patients who met the study criteria will be randomly divided into treatment and control groups, with the treatment group receiving Tongxinluo capsules combined with metoprolol tartrate and the control
Experimental Other
Tongxinluo capsules combined with metoprolol tartrate
Sponsors
Pengcheng Ren
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1.meeting the diagnostic criteria for coronary angina 2. 18 to 70 years old 3.Bruce Protocol 3 to 12 min 4. patients agreed to join this study and signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1.patients with drug allergy in this study 2. patients with acute cardiomyopathy or congestive heart failure within 3 months 3. ALT, AST or Cr up to 1.5 times the normal upper limit 4. those with communication impairment or poor compliance 5. women who are pregnant, preparing for pregnancy or breastfeeding.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Lipid levels 12 weeks TC; TG; LDL-C; and HDL-C. | — |
Secondary
| Measure | Time frame |
|---|---|
| Before and after treatment and at follow-up, the patients' left ventricular end-diastolic diameter (LVEDD) 12 weeks left ventricular end-systolic diameter (LVESD) | — |
Countries
China
Contacts
Public ContactPengcheng Ren
No.1073 Erhuan South Road, Tangxiang Street, Dazu District, Chongqing
Outcome results
None listed